Tim Meyer
Impact in
- Hepatology top 0.02%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Hepatology 121
- Hepatocellular Carcinoma Treatment and Prognosis 121
- Epidemiology 57
- Neuroendocrine Tumor Research Advances 53
- Co-authors
- Arndt Vogel (14 shared papers)Andrew Kenneth Burroughs (18 shared papers)Gonzalo Sapisochín (3 shared papers)Anna Lena Saborowski (3 shared papers)Riad Salem (1 shared paper)Josep Maria Llovet (17 shared papers)Gordon J.S. Rustin (5 shared papers)Tu Vinh Luong (20 shared papers)
- Journals
- Annals of Oncology (37 papers)Journal of Hepatology (26 papers)British Journal of Cancer (18 papers)Clinical Cancer Research (10 papers)European Journal of Cancer (8 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Tim Meyer
233 papers receiving 24.2k citations
Tim Meyer's Hit Papers
Peers
Comparison fields: 5 of 128
- Hepatology 12.2k
- Oncology 5.5k
- Epidemiology 2.8k
- Cancer Research 1.1k
- Immunology and Allergy 285
Countries citing papers authored by Tim Meyer
This map shows the geographic impact of Tim Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Meyer more than expected).
Fields of papers citing papers by Tim Meyer
This network shows the impact of papers produced by Tim Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Meyer. The network helps show where Tim Meyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Tim Meyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 239 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Hit paper breakdown → | 2017 | 3584 |
| 2 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Hit paper breakdown → | 2018 | 1919 |
| 3 | Hepatocellular carcinoma Hit paper breakdown → | 2022 | 1680 |
| 4 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 1525 |
| 5 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 968 |
| 6 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 834 |
| 7 | Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma Hit paper breakdown → | 2021 | 759 |
| 8 | Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies Hit paper breakdown → | 2006 | 663 |
| 9 | Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Hit paper breakdown → | 2011 | 615 |
| 10 | A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability Hit paper breakdown → | 2012 | 548 |
| 11 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial Hit paper breakdown → | 2017 | 412 |
| 12 | EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Hit paper breakdown → | 2024 | 382 |
| 13 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 364 |
| 14 | Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial Hit paper breakdown → | 2019 | 355 |
| 15 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference Hit paper breakdown → | 2020 | 331 |
| 16 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 326 |
| 17 | 2013 | 301 | |
| 18 | 2011 | 278 | |
| 19 | 2013 | 273 | |
| 20 | 2000 | 236 |
About Tim Meyer
Tim Meyer is a scholar working on Hepatology, Epidemiology, Oncology, Immunology and Allergy and Cancer Research, having authored 239 papers that have together received 24.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (121 papers), Neuroendocrine Tumor Research Advances (53 papers), Cancer Immunotherapy and Biomarkers (18 papers), Pancreatic and Hepatic Oncology Research (10 papers), Cell Adhesion Molecules Research (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Cancer Cells and Metastasis (4 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Hepatology (12.2k citations), Oncology (5.5k citations), Epidemiology (2.8k citations), Cancer Research (1.1k citations) and Immunology and Allergy (285 citations). Tim Meyer has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Arndt Vogel, Andrew Kenneth Burroughs, Gonzalo Sapisochín, Anna Lena Saborowski, Riad Salem, Josep Maria Llovet, Gordon J.S. Rustin, Tu Vinh Luong, Bruno Sangro and Martyn Evan Caplin. Their work appears in journals such as Annals of Oncology, Journal of Hepatology, British Journal of Cancer, Clinical Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.